Press Releases: A Leading Indian Biopharmaceutical Company, Intas Pharmaceutical- Biotech Division, Has Signed A Contract Research And Contract Manufacturing Agreement With A European Company

Pharmalicensing.com

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

UTEK Corporation

Press releases

Stay current with the latest press releases from within the industry.

A leading Indian Biopharmaceutical company, Intas Pharmaceutical- Biotech division, has signed a Contract Research and Contract Manufacturing Agreement with a European company

Release issued 1st June 2005

For more information please contact business@intasbiopharma.co.in

Company details

If you want to find out more about the company visit Intas BioPharmaceuticals profile.

Latest Intas BioPharmaceuticals press releases

(2nd November 2009) Intas Biopharmaceuticals Limited (IBPL) and European pharmaceutical major Kwizda Pharma GmbH has jointly completed Phase I clinical trial study of NEUKINE®, biosimilar form of recombinant GCSF

(2nd November 2009) Intas Biopharma to pump in Rs 160 cr for dedicated facility for Monoclonal Antibodies (MAbs)

More Press Releases

Latest

Gaining a better picture of lung disease

Hess named HSFC Highest-Rated New Investigator

Time to ramp up health innovation

Postovit named Premier Young Researcher

Hachinski elected president of World Federation of Neurology

Most viewed

TDS® TESTOSTERONE EXCEEDS ANDROGEL® OUTCOMES

GenMont probiotics products receive China market entry approval

Surveyed neurologists in both the United States and Europe indicate that a once-daily transdermal formulation of Levodopa would earn a 30 percent patient share in Parkinson’s Disease

TDS® TESTOSTERONE WILL LIKELY NOT REQUIRE BLACK BOX WARNINGS FROM FDA

Medigreen announces MAF, a new botanical-based anti-allergy formulation

Clients in focus...

Get the Flash Player to see this rotator.

BioTrinity

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd All rights reserved. Terms and Conditions | Contact us